{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:26:49Z","timestamp":1790015209500,"version":"4.0.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0198642","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T13:42:28Z","timestamp":1527860548000},"page":"e0198642","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3847-1065","authenticated-orcid":true,"given":"Seiichi","family":"Mawatari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Tabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ijuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Uto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Hiramine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oki","family":"Taniyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"H Kumada","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00535-016-1303-0","article-title":"New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir","volume":"52","author":"S Mawatari","year":"2017","journal-title":"Journal of gastroenterology"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"M Mizokami","year":"2015","journal-title":"The Lancet Infectious diseases"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jvh.12549","article-title":"Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir\/Sofosbuvir Containing Regimens in Phase 3 Studies","volume":"23","author":"M Mizokami","year":"2016","journal-title":"Journal of viral hepatitis"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hep.22339","article-title":"Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon\/ribavirin combination therapy","volume":"48","author":"A El-Shamy","year":"2008","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","article-title":"Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b","volume":"54","author":"F Suzuki","year":"2012","journal-title":"Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1128\/JCM.39.11.3858-3864.2001","article-title":"Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a","volume":"39","author":"MI Lusida","year":"2001","journal-title":"Journal of clinical microbiology"},{"issue":"13","key":"ref9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/hepr.12685","article-title":"Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection","volume":"46","author":"J Ito","year":"2016","journal-title":"Hepatology research: the official journal of the Japan Society of Hepatology"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"C Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"RA Fridell","year":"2010","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"RA Fridell","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"AM Lam","year":"2012","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"X Tong","year":"2014","journal-title":"The Journal of infectious diseases"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","article-title":"L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions","volume":"213","author":"ES Svarovskaia","year":"2016","journal-title":"The Journal of infectious diseases"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3851\/IMP3149","article-title":"In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6","volume":"22","author":"S Xu","year":"2017","journal-title":"Antiviral therapy"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"EF Donaldson","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"key":"ref18","unstructured":"Harvoni IFo. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.harvoni.jp\/~\/media\/files\/gilead\/harvoni\/product\/download\/index\/str_interview_form_v7.pdf?la=ja-jp\" xlink:type=\"simple\">https:\/\/www.harvoni.jp\/~\/media\/files\/gilead\/harvoni\/product\/download\/index\/str_interview_form_v7.pdf?la=ja-jp<\/ext-link>, Gilead Sciences, Tokyo, Japan"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/hepr.12898","article-title":"Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy","volume":"47","author":"E Iio","year":"2017","journal-title":"Hepatology research: the official journal of the Japan Society of Hepatology"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/jmv.24617","article-title":"Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan","volume":"89","author":"N Akuta","year":"2017","journal-title":"Journal of medical virology"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","article-title":"NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b","volume":"52","author":"E Ogawa","year":"2017","journal-title":"Journal of gastroenterology"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.28625","article-title":"Real-world effectiveness of ledipasvir\/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients","volume":"64","author":"LI Backus","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response","volume":"151","author":"NA Terrault","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir","volume":"151","author":"C Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis","volume":"62","author":"KR Reddy","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"key":"ref26","unstructured":"Sciences G. HARVONI combination tablets (sofosbuvir+ledipasvir), for oral use: PRESCRIBING INFORMATION 2015."},{"key":"ref27","unstructured":"Guidance: H. recommendations for testing, managing, and treating hepatitis C. AASLD and IDSA. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/wwwhcvguidelinesorg\" xlink:type=\"simple\">http:\/\/wwwhcvguidelinesorg<\/ext-link>."},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","year":"2017","journal-title":"Journal of hepatology"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00535-016-1225-x","article-title":"Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1","volume":"52","author":"E Iio","year":"2017","journal-title":"Journal of gastroenterology"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"JM Pawlotsky","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00535-015-1108-6","article-title":"Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice","volume":"50","author":"Y Kai","year":"2015","journal-title":"Journal of gastroenterology"},{"key":"ref32","article-title":"Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy","author":"G Suda","year":"2017","journal-title":"Journal of gastroenterology"},{"key":"ref33","article-title":"Retreatment with sofosbuvir\/ledipasvir with or without lead-in interferon-beta injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir\/asunaprevir therapy","author":"H Uemura","year":"2017","journal-title":"Hepatology research: the official journal of the Japan Society of Hepatology"},{"key":"ref34","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir\/asunaprevir therapy: pilot study","author":"Y Kawakami","year":"2017","journal-title":"Journal of gastroenterology"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/hepr.12673","article-title":"Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir\/asunaprevir therapy by a two-hit mechanism","volume":"46","author":"Y Uchida","year":"2016","journal-title":"Hepatology research: the official journal of the Japan Society of Hepatology"},{"key":"ref36","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection","author":"H Kumada","year":"2017","journal-title":"Journal of gastroenterology"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2010.03.022","article-title":"Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients","volume":"53","author":"H Abe","year":"2010","journal-title":"Journal of hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0198642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T01:09:18Z","timestamp":1540343358000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0198642"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0198642","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}